Investors | Syncona

As of 31 March 2022

£1.3bn

Net assets

194p

NAV per share

0.3%

NAV per share growth over previous 12 months

£525m

Value of life science portfolio

0.8%

Return from life science portfolio over previous 12 months

£785m

Capital pool

Freeline reports Q2 2022 Financial Results

09.08.22

Achilles reports Q2 2022 Financial Results

09.08.22

Autolus Reports Q2 2022 Financial Results

04.08.22

Holding(s) in Company

03.08.22

Result of AGM

02.08.22

Total Voting Rights

02.08.22

Issue of shares pursuant to incentive scheme

15.07.22

Freeline presents data in haemophilia B

11.07.22

Holding(s) in Company

07.07.22

Publication of 2022 Annual Report & Notice of AGM

30.06.22

Director Declaration

22.06.22

Final Results

16.06.22

Autolus presents clinical data updates at EHA

10.06.22

Holding(s) in Company

08.06.22

Notice of Results

19.05.22

Syncona invests in $56 million SwanBio Series B

18.05.22

Autolus to present clinical data at EHA Congress

12.05.22

Freeline reports Q1 2022 Financial Results

11.05.22

Search